New hope for pancreatic cancer? trial tests two drug combos Head-to-Head
NCT ID NCT07076212
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tests two different chemotherapy combinations in people with advanced pancreatic cancer that has spread or cannot be removed by surgery. About 52 participants will be randomly assigned to receive either NALIRIFOX or a modified version of gemcitabine, nab-paclitaxel, and cisplatin. The goal is to see which combination shrinks tumors better and improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hollings Cancer Center at Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical University of South Carolina Hollings Cancer Center
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.